PSA (prostate specific antigen) has not demonstrated sufficient sensitivity and specificity to be useful in the evaluation of prostate carcinoma. To enhance the accuracy of serum PSA the Authors have used a quotient of serum PSA (ng/ml) and prostate volume (calculated by transrectal ultrasound) which is named PSAD (prostate specific antigen density).
BensonM.C.: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol., 147: 815–816, 1992.
2.
BensonM.C.: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol., 147: 817–821, 1992.
